4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was recently discussed by Jim Cramer, who advised treating it as a speculative investment due to its $300 million market cap. The company reported positive interim results from its Phase 2a SPECTRA trial of 4D-150 for diabetic macular edema, showing vision improvements and reduced injections compared to standard treatment.

While FDMT shows promise, other AI stocks may offer better returns with less risk. For a potentially undervalued AI stock poised to benefit from tariffs and onshoring trends, consider a free report on the best short-term AI stock. Explore 30 stocks projected to double in 3 years and 11 hidden AI stocks for further investment opportunities.

Read more at Yahoo Finance: “This is a Pure Spec”